

Scan to visit the HCP website

Now with NUVESSA®
BV dosing can be...

One & Done[a]

The One and Only Single Dose Metronidazole Vaginal Gel (MVG) for Bacterial Vaginosis (BV) Patients 12 and Older

- ✔ **Achieving good patient compliance with multiday regimens can be challenging.[1]**
- ✔ **Single-dose BV treatments may provide an option for patients who desire greater convenience than multidose regimens.[2]**

Patient Rating of Convenience by BV Treatment Regimen[3,b]

	Treatment Protocol			
Patient Rating of Convenience	1.3% once daily/1 day (n=43)	1.3% once daily/3 days (n=48)	1.3% once daily/5 days (n=49)	0.75% once daily/5 days (n=49)
Very convenient	81.4%	45.8%	32.7%	34.7%

[a] In a clinical study NUVESSA® demonstrated significantly higher cure rates over a vehicle gel.[4]
[b] A phase 2, randomized, controlled, investigator-blinded, dose-ranging study evaluated women with BV (N=255) who were being treated with different metronidazole-based regimens. The primary endpoint was therapeutic cure (defined as clinical plus bacteriologic cure) at Day 21. There were multiple secondary efficacy measures, including a patient end-of-study questionnaire on treatment satisfaction.[3]

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NUVESSA® (metronidazole vaginal gel 1.3%) is an intravaginal treatment indicated for the treatment of bacterial vaginosis in females 12 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINICATIONS

NUVESSA is contraindicated in:

- Patients with a history of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives.
- Patients using disulfiram or within 2 weeks of disulfiram use.
- Patients using alcohol. Alcoholic preparations (e.g., ethanol, propylene glycol) and beverages should not be consumed during and for at least 24 hours after NUVESSA therapy.

WARNINGS and PRECAUTIONS

Central and Peripheral Nervous System Effects

Convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy have been reported in patients treated with oral or intravenous metronidazole. NUVESSA should be administered with caution to patients with central nervous system diseases. Discontinue promptly if abnormal neurologic signs development.



NUVESSA®
(metronidazole vaginal gel 1.3%)

Please see Important Safety Information continued on adjacent page and accompanying full Prescribing Information.



Now with NUVESSA® BV dosing can be...

Scan to visit the HCP website

One & Done[a]

Give patients the option of convenience with NUVESSA® — the one and only single-dose Metronidazole Vaginal Gel (MVG) for Bacterial Vaginosis (BV)

- ✔ *In a clinical study, a single dose of 1.3% MVG demonstrated comparable efficacy to a 5-dose regimen of 0.75% MVG[3]*
- ✔ *1 pre-filled applicator offers ease of use at bedtime[5]*
- ✔ *1 targeted dose at the site of infection minimizes unnecessary drug exposure[6]*

NUVESSA® Patient Savings Program

Visit: NUVESSA.COM

Text "NUVESSA" to 31700

for your patients who prefer to get the copay card on their mobile device.

Eligible patients may pay as little as $25[c] for their prescription

[c] The patient is responsible for the first $25 of their co-pay and cash-paying patients should pay approximately $55. For cash paying patients or insured patients when NUVESSA® is not covered by primary insurance, patients may still use this savings card but may have an outstanding balance. Please see Program Terms, Conditions, and Eligibility Criteria on back of savings card.



To ensure your patients receive NUVESSA®, add "Dispense as written"

Make sure your patients get the only single-dose, single-use metronidazole vaginal gel 1.3% treatment for BV

References: 1. Bartley JB, et al. *Sex Transm Dis.* 2004;31(8):488-491. **2.** Muzny CA. *Sex Trans Dis.* 2020;47(7):441-446. **3.** Chavoustie SE, et al. *J Low Genit Tract Dis.* 2015;19(2):129-134. **4.** Schwebke JR, et al. *Sex Trans Dis.* 2015;42:376-381. **5.** FDA. Nuvessa Prescribing Information. **6.** Hirai J, et al. *J Infect Chemother.* 2025;31(11):102826

INDICATION AND IMPORTANT SAFETY INFORMATION (cont'd)

Carcinogenicity in Animals

Metronidazole has been shown to be carcinogenic at high doses administered orally in mice and rats. Unnecessary use of metronidazole should be avoided.

Drug/Laboratory Test Interactions

Metronidazole may interfere with certain serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed.

Please see Important Safety Information continued on adjacent page and accompanying full Prescribing Information.

Adverse Reactions

The most common adverse reactions (≥1%) observed in adult clinical studies were vulvovaginal candidiasis, headache, vulvovaginal pruritus, nausea, diarrhea, and dysmenorrhea.

The most common adverse reactions (≥1%) observed in pediatric clinical studies was vulvovaginal discomfort.

This is not a complete list of risks.

Please see attached full Prescribing Information for detailed information and online at Nuvessa.com.



NUVESSA®
(metronidazole vaginal gel 1.3%)

Alembic Therapeutics

NUVESSA® is a trademark of Alembic Therapeutics, LLC.
© 2026 Alembic Therapeutics. All Rights Reserved
US-NUV-00004 v1.0